EGFR and lung carcinoma: Comparison of LiquidHALLMARK against the FDA-approved cobas EGFR Mutation Test v2 for 50 lung cancer specimens demonstrated an overall concordance of 84.00% (PPA 96.88%; NPA 61.11%), with eight discordant calls (LiquidHALLMARK VAF 0.05–0.33%) between LiquidHALLMARK and cobas.